Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ)
CNY 3.83
(-1.03%)
CNY 3.83
(-1.03%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.72 Billion | 49.61 Billion | 49.58 Billion | 43.57 Billion | 50.19 Billion | 30.95 Billion |
| Cost of Revenue | 9.82 Billion | 8.45 Billion | 7.31 Billion | 3.22 Billion | 8.17 Billion | 2.86 Billion |
| Gross Profit | 39.89 Billion | 41.15 Billion | 42.27 Billion | 40.35 Billion | 42.01 Billion | 28.08 Billion |
| Operating Expenses | 50.11 Billion | 10.15 Billion | 10.43 Billion | 36.77 Billion | 30.66 Billion | 2.61 Billion |
| Selling, General and Administrative Expenses | 473.69 Million | 333.97 Million | 541.05 Million | 628.19 Million | 600.75 Million | 500.29 Million |
| Research and Development Expenses | - | - | - | - | 5.66 Million | 19.22 Million |
| Other Expenses | 41.23 Billion | 9.82 Billion | 9.89 Billion | 36.14 Billion | 30.06 Billion | -24.28 Billion |
| Cost and Expenses | 50.11 Billion | 18.61 Billion | 17.74 Billion | 39.99 Billion | 38.84 Billion | 5.48 Billion |
| Operating Income | 1.21 Billion | 31.18 Billion | 32.91 Billion | 3.88 Billion | 12.05 Billion | 2.65 Billion |
| Interest Expense | - | 31.2 Billion | 423.79 Million | 170.54 Million | 101.32 Million | - |
| Income Tax Expense | -586.5 Million | -285.84 Million | -537.09 Million | 331.55 Million | 714.89 Million | 259.08 Million |
| Earnings before Tax | -1.86 Billion | 224.77 Million | 343.12 Million | 1.44 Billion | 3.63 Billion | 2.63 Billion |
| Net Income | -651.75 Million | 510.61 Million | 880.21 Million | 1.11 Billion | 2.91 Billion | 1.32 Billion |
| Earnings Per Share Basic | -0.13 | 0.10 | 0.18 | 0.23 | 0.59 | 0.27 |
| Earnings Per Share Diluted | -0.13 | 0.10 | 0.18 | 0.23 | 0.59 | 0.27 |
| Weighted Average Shares Outstanding | 5.01 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.93 Billion | 4.91 Billion |
| Weighted Average Shares Outstanding (Diluted) | 5.01 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.93 Billion | 4.91 Billion |
| Gross Margin | 0.80 | 0.83 | 0.85 | 0.93 | 0.84 | 0.91 |
| EBIT Margin | 0.02 | 0.63 | 0.67 | 0.09 | 0.24 | 0.93 |
| Profit Margin | -0.01 | 0.01 | 0.02 | 0.03 | 0.06 | 0.04 |
| EBITDA | 1.21 Billion | 726.53 Million | 31.98 Billion | 2.93 Billion | 3.67 Billion | 2.7 Billion |
| Earnings Before Tax Margin | 0.02 | 0.63 | 0.66 | 0.09 | 0.24 | 0.09 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 4.53 Billion | 11.57 Billion | 17.37 Billion | 48.23 Billion | 49.72 Billion | 7.75 Billion |
| Cost of Revenue | 1.58 Billion | 3.79 Billion | 18.98 Billion | 2.66 Billion | 9.82 Billion | 1.67 Billion |
| Gross Profit | 2.95 Billion | 7.77 Billion | -1.6 Billion | 45.57 Billion | 39.89 Billion | 6.08 Billion |
| Operating Expenses | 1.37 Billion | 6.53 Billion | -3.42 Billion | -47.04 Billion | -48.5 Billion | 1.04 Billion |
| Selling, General and Administrative Expenses | 20.68 Million | 417.39 Million | 406.86 Million | 1.3 Billion | - | 1.02 Billion |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 1.35 Billion | -4.52 Billion | -19.67 Billion | -47.04 Billion | -48.5 Billion | -5.13 Billion |
| Cost and Expenses | 2.95 Billion | 10.32 Billion | -17.52 Billion | -49.64 Billion | -51.56 Billion | 2.71 Billion |
| Operating Income | 163.99 Million | -294.95 Million | -122.18 Million | 1.18 Billion | 1.21 Billion | -156.5 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 87.2 Million | 230 Million | 45.34 Million | -1.18 Billion | -1.21 Billion | -117.23 Million |
| Earnings before Tax | 153.9 Million | -308.94 Million | -152.33 Million | -1.42 Billion | -1.86 Billion | -162.51 Million |
| Net Income | 31.91 Million | -275.14 Million | -89.87 Million | -232.34 Million | -651.78 Million | -25.59 Million |
| Earnings Per Share Basic | 0.01 | -0.06 | -0.02 | -0.05 | - | -0.01 |
| Earnings Per Share Diluted | 0.01 | -0.06 | -0.02 | -0.05 | - | -0.01 |
| Weighted Average Shares Outstanding | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion |
| Weighted Average Shares Outstanding (Diluted) | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion | 4.94 Billion |
| Gross Margin | 0.65 | 0.67 | -0.09 | 0.94 | 0.80 | 0.78 |
| EBIT Margin | 0.35 | 0.11 | 0.11 | 0.02 | - | 0.65 |
| Profit Margin | 0.01 | -0.02 | -0.01 | -0.00 | -0.01 | -0.00 |
| EBITDA | 1.57 Billion | 1.24 Billion | 1.92 Billion | 1.18 Billion | - | 5.03 Billion |
| Earnings Before Tax Margin | 0.04 | -0.03 | -0.01 | 0.02 | 0.02 | -0.02 |
IMAS
1709
5214
TGGI
ROG
6874